Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KOD
KOD logo

KOD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kodiak Sciences Inc (KOD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
42.360
1 Day change
1.34%
52 Week Range
45.600
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Kodiak Sciences Inc (KOD) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite positive analyst ratings and promising drug developments, the recent insider selling, negative price momentum, and financial losses suggest caution. The stock may require further stabilization before being a compelling long-term investment.

Technical Analysis

The technical indicators show mixed signals. The MACD is positive and contracting, indicating potential bullish momentum. However, the RSI is neutral, and the stock has experienced significant recent price declines (-5.09% in regular trading and -2.60% post-market). Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is currently trading below key resistance levels (R1: 42.3).

Options Data

Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Put-Call Volume Ratio (1.81) indicates bearish sentiment in the options market, with more puts being traded than calls.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
9

Positive Catalysts

  • Positive Phase 3 results for GLOW2 study in diabetic retinopathy and accelerated Biologics License Application timing for tarcocimab. Analysts have raised price targets significantly, citing strong drug development progress.

Neutral/Negative Catalysts

  • Insider selling has surged by 45259.39% in the last month, signaling potential lack of confidence from management. The stock has also experienced significant recent price declines, and options data suggests bearish sentiment.

Financial Performance

In Q4 2025, the company reported a net loss of $56.7 million, with EPS at -$1.04 (improved by 23.81% YoY). While cash reserves of $209.9 million are expected to sustain operations into 2027, the company is still facing high R&D expenses ($45.5 million in Q4 2025). Revenue remains at $0, indicating no commercialized products yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish, with multiple firms raising price targets (UBS to $80, H.C. Wainwright to $58, Jefferies to $56). Positive updates on tarcocimab and KSI-501 have driven these upgrades, with expectations of strong long-term potential.

Wall Street analysts forecast KOD stock price to fall
7 Analyst Rating
Wall Street analysts forecast KOD stock price to fall
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 42.360
sliders
Low
14
Averages
27.86
High
50
Current: 42.360
sliders
Low
14
Averages
27.86
High
50
UBS
Buy
maintain
$50 -> $80
AI Analysis
2026-03-27
Reason
UBS
Price Target
$50 -> $80
AI Analysis
2026-03-27
maintain
Buy
Reason
UBS raised the firm's price target on Kodiak Sciences to $80 from $50 and keeps a Buy rating on the shares. UBS is bullish on both Tarcocimab VEGF and IL6, the analyst tells investors in a research note.
H.C. Wainwright
Matthew Caufield
Buy
maintain
$38 -> $58
2026-03-27
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$38 -> $58
2026-03-27
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Caufield raised the firm's price target on Kodiak Sciences to $58 from $38 and keeps a Buy rating on the shares. The firm cites the positive tarcocimab update for the target boost. The Phase 3 GLOW2 trial in diabetic retinopathypatients served to validate the reformulated tarcocimab tedromer design, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KOD
Unlock Now

People Also Watch